pilot-plant-of-chime-biologics
pilot-plant-of-chime-biologics
NewsRoom
Key Points in the Implementation of Biopharmaceutical Technology Transfer
Key Points in the Implementation of Biopharmaceutical Technology Transfer
Going Global – Chime Biologics Embraces Innovation and Quality with Partners
Going Global-Chime Biologics Embraces Innovation and Quality with Partners Foreign biopharmaceutical companies seek CDMO partners with long-term prospects, technology levels, and quality systems aligned with international standards. Jimmy Wei, President of Chime Biologics, highlighted that the company’s competitive edge arises from ensuring product quality, leveraging efficiencies, and maintaining stringent cost controls. July 5, 2024, Shanghai, […]
CHO Cell Line Development: Process and Key Technical Points Overview
CHO Cell Line Development: Process and Key Technical Points Overview
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy The agreement combines Domain Therapeutics’ candidate DT-7012 with Chime Biologics’ internationally-recognized manufacturing expertise In June 2023, Domain nominated DT-7012, a Treg depleting anti-CCR8 monoclonal antibody (mAb) with best-in-class potential, which enters Phase I studies in 2025 The CCR8 GPCR […]